An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
This study has been completed.
Sponsor:
Guangdong General Hospital
Information provided by (Responsible Party):
Wei Shi, Guangdong General Hospital
ClinicalTrials.gov Identifier:
NCT01502579
First received: December 29, 2011
Last updated: August 27, 2013
Last verified: August 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function. This study is aimed to identify the potential relationship between pathological variants and clinical data in IgA nephropathy.
| Condition |
|---|
|
IgA Nephropathy |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | An Observational Study of the Relationship Between Pathological Variants and Clinical Data at Presentation and Follow-up in IgA Nephropathy |
Resource links provided by NLM:
MedlinePlus related topics:
Kidney Diseases
Drug Information available for:
Immunoglobulin A
U.S. FDA Resources
Further study details as provided by Guangdong General Hospital:
Primary Outcome Measures:
- glomerular filtration rate decline or end-stage renal disease or doubling of serum creatinine [ Time Frame: after the biopsy ] [ Designated as safety issue: No ]
| Enrollment: | 603 |
| Study Start Date: | September 2011 |
| Study Completion Date: | August 2013 |
| Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
The population from which the cohort will be selected is these who have received renal biopsy in Guangdong General Hospital
Criteria
Inclusion Criteria:
- biopsy-proven IgA nephropathy;
Exclusion Criteria:
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01502579
Please refer to this study by its ClinicalTrials.gov identifier: NCT01502579
Locations
| China, Guangdong | |
| Guangdong General Hospital | |
| Guangzhou, Guangdong, China, 510080 | |
Sponsors and Collaborators
Guangdong General Hospital
Investigators
| Principal Investigator: | Wei Shi, MD,PhD | Guangdong General Hospital |
More Information
No publications provided
| Responsible Party: | Wei Shi, Professor, Guangdong General Hospital |
| ClinicalTrials.gov Identifier: | NCT01502579 History of Changes |
| Other Study ID Numbers: | GGH201106 |
| Study First Received: | December 29, 2011 |
| Last Updated: | August 27, 2013 |
| Health Authority: | China: Ethics Committee |
Keywords provided by Guangdong General Hospital:
|
IgA nephropathy |
Additional relevant MeSH terms:
|
Glomerulonephritis, IGA Kidney Diseases Autoimmune Diseases Glomerulonephritis |
Immune System Diseases Nephritis Urologic Diseases |
ClinicalTrials.gov processed this record on March 03, 2015